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Background:  The heart undergoes remodeling post-transplantation. We investigated molecular processes associated with remodeling including: 
cardiac growth, apoptosis, inflammation and oxidative stress as well as biomarker changes in de novo cardiac transplant (CTX) recipients compared 
with healthy volunteers (HV) and explanted non failing human hearts.
Methods:  One hundred adult CTX recipients aged 53.3±12.6 years and treated with either tacrolimus (Tac) or cyclosporine (CsA) were recruited. 
Biomarkers included hs-CRP, osteopontin, ICAM-I, interleukin (IL)-6, IL-18, MCP-1, TBARS, nitrotyrosine, glutathione and isoprostanes were sampled 
pre-transplantation and at weeks 2, 4, 12, 26, and 52. Cardiac subcellular events were investigated by quantification of phosphorylated MEK-1/2, 
ERK-1/2, JNK C-Src-MEK 3/6, P38 MAPK, Bax/Bcl2, and AKT on endomyocardial biopsies. Observations from CTX patients were compared with 30 
HV and 6 explanted non-failing human hearts with normal LV function.
Results:  Data are presented in the table. There were no significant differences between Tac vs. CsA immunoprophylaxis in any of the parameters 
investigated.
Conclusions:  Compared with HV, de novo CTX recipients exhibit a significant increase in biomarkers related to subclinical inflammation and 
oxidative stress which persist up to 12 months following CTX. Similarly there is an up regulation of cardiac signalling molecules related to growth, 
apoptosis and cell survival. 
Biomarkers and Cardiac Subcellular Events
hs-CRP (mg/l)
Osteopontin (ng/
ml)
IL-6 (pg/ml)
T-Bars (nmol/
ml)
P-ERK 1/2 
(density)
P-P38
MAPK (density)
AKT (density)
HV/Explanted Heart 1.66±3.51 1.60±1.36 0.39±0.31 1.73±0.18 0.35±0.34 0.27±0.40 0.14±0.06
Pre-CTX 27.6±43.6 11.5±10.8 3.75±1.27 3.84±1.82 - - -
Week 2 21.2±31.3 15.8±14.8 5.72±1.65 4.40±2.01 0.80±0.58 0.51±0.50 0.57±0.43
Week 4 12.0±20.7 13.8±12.9 3.48±1.04 3.93±1.41 0.95±0.63 0.49±0.45 0.61±0.51
Week 12 4.52±6.36 11.0±9.3 0.99±0.88 3.79±1.80 0.82±0.60 0.65±0.73 0.59±0.46
Week 52 3.47±4.38 9.60±9.76 0.70±0.64 3.20±1.28 0.83±0.60 0.70±0.69 0.64±0.54
Data are mean ± SD.
